Reata Pharmaceuticals, Inc. RETA announced that it has completed its previously requested pre-new drug application (NDA) meeting with the FDA related to its Friedreich’s ataxia (“FA”) candidate, ...
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback